Structural & Congenital Heart Disease

Transsubclavian or transaxillary (TAx) access has become the preferred route for balloon-expandable TAVR when femoral access isn’t feasible, a new analysis found. Outcomes were generally favorable with TAx TAVR compared to other alternative access techniques, with the exception of higher stroke rates, researchers reported in JACC: Cardiovascular Interventions.

With CMS just months away from an updated national coverage determination for transcatheter aortic valve replacement (TAVR), a new analysis in the New England Journal of Medicine suggests the relationship between procedural volume and TAVR outcomes remains important in the United States.

When pregnant women inhale secondhand smoke—including from prospective fathers—it may be even more dangerous to their offspring than if the women smoke themselves, according to a meta-analysis published in the European Journal of Preventive Cardiology.

CMS has proposed an update to its national coverage policy for transcatheter aortic valve replacement (TAVR), which would require hospitals to perform 50 aortic valve replacements each year to maintain a TAVR program—including at least 20 TAVRs.

An expert consensus statement published by the Society for Cardiovascular Angiography and Interventions (SCAI) offers guidance for the safe and effective use of patent foramen ovale (PFO) closure devices to prevent recurrent stroke.

Patients with severe but asymptomatic aortic stenosis have better survival two and three years later if an aortic valve replacement (AVR) is initially recommended instead of a “watchful waiting” approach, according to a single-center study published in The Annals of Thoracic Surgery.

NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.

NEW ORLEANS — Two trials evaluating transcatheter aortic valve replacement (TAVR) in low-risk patients haven’t just shifted the TAVR versus surgical AVR discussion. They’ve completely flipped it, said experts here at the American College of Cardiology’s scientific sessions.

Patients who received aortic valve repair or replacement (AVR) based on Class II indications fared better than those who underwent surgery for Class I triggers in a single-center study, suggesting earlier intervention may be warranted in asymptomatic individuals with chronic aortic regurgitation.

The FDA has expanded the indication for the MitraClip to include heart failure patients with moderate-to-severe secondary mitral regurgitation, the agency announced March 14. Abbott’s transcatheter mitral valve repair device was approved in 2013, but only for primary mitral regurgitation.

The American College of Cardiology (ACC) will begin offering a new Transcatheter Valve Certification to U.S. hospitals in mid-2019, the College announced March 13.

Edwards Lifesciences has invested $35 million for an exclusive right to acquire Corvia Medical, which is engaged in a U.S. pivotal trial for its InterAtrial Shunt Device (IASD) to treat heart failure.